LYKALABS

Lyka Labs financials

Market cap
₹300 Cr
Sector
Healthcare

What Lyka Labs does

Lyka Labs Limited manufactures and markets pharmaceutical formulations for both human and veterinary use, sold under company brands domestically and exported to select international markets, including government-tender business. Manufacturing is carried out at the company's plant in Ankleshwar, Gujarat, supported by a dedicated Research & Development Centre in Andheri, Mumbai. The group includes related pharmaceutical entities Lyka Exports Limited, Lyka BDR International Limited and Lyka Generics Limited, alongside an associate relationship with Ipca Laboratories Limited.

Segments

  • Human pharmaceuticals
  • Veterinary pharmaceuticals
  • Export business
Manufacturing plants
1 (Ankleshwar, Gujarat)
R&D centres
1 (Andheri, Mumbai)
Business lines
Human + Veterinary formulations
Related pharma group entities
3 (Lyka Exports, Lyka BDR International, Lyka Generics)
Export presence
International markets incl. government tenders
Founded 1976Headquarters Mumbai, Maharashtra Company website

Quarterly results

Q1 FY27: revenue up 28.1%, net profit up 107.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue41 34 33 33 37 −11%31 −9%28 −16%42 +28%
EBITDA5 5 4 4 -3 −151%2 −68%-6 −258%5 +24%
Net profit2 3 2 1 -3 −269%-0 −106%-8 −498%2 +107%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −16.9% 1Y

₹60₹80₹100Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹99.76 on 10 Sept 2025 → ₹82.9. High ₹100.43 (19 Sept 2025), low ₹44.95 (30 Mar 2026).

Financials, as filed

Revenue grew 11.3% a year over 3 years, FY23 to FY26. Operating margin narrowed to -2.8%.

Year endingFY23FY24FY25FY26
Revenue₹93 Cr₹111 Cr₹139 Cr₹128 Cr
Operating profit₹17 Cr₹16 Cr₹18 Cr₹-4 Cr
Operating margin18.1%14.1%12.9%-2.8%
Interest₹12 Cr₹5 Cr₹2 Cr₹3 Cr
Depreciation₹14 Cr₹13 Cr₹7 Cr₹8 Cr
Net profit₹-13 Cr₹-3 Cr₹8 Cr₹-10 Cr
Net margin-14.2%-2.4%5.7%-8.1%
Cash from operations₹9 Cr₹2 Cr₹2 Cr₹5 Cr
Free cash flow₹15 Cr₹-7 Cr₹-10 Cr₹-6 Cr
ROCE5.0%4.0%10.0%-6.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹29 Cr₹29 Cr₹31 Cr₹33 Cr₹36 Cr₹36 Cr
Reserves₹-54 Cr₹-15 Cr₹15 Cr₹35 Cr₹65 Cr₹57 Cr
Borrowings₹163 Cr₹130 Cr₹75 Cr₹59 Cr₹32 Cr₹49 Cr
Other liabilities₹52 Cr₹42 Cr₹31 Cr₹30 Cr₹35 Cr₹33 Cr
Total liabilities₹190 Cr₹186 Cr₹152 Cr₹157 Cr₹168 Cr₹175 Cr
Fixed assets₹98 Cr₹94 Cr₹68 Cr₹58 Cr₹87 Cr₹87 Cr
Capital work in progress₹26 Cr₹18 Cr₹16 Cr₹23 Cr₹1 Cr₹2 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹66 Cr₹74 Cr₹67 Cr₹76 Cr₹80 Cr₹86 Cr
Total assets₹190 Cr₹186 Cr₹152 Cr₹157 Cr₹168 Cr₹175 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters added +0.29 pp while the public trimmed −0.29 pp. The shareholder count grew 4% to 29,369.

Promoters
58.5%
FIIs
0.2%
DIIs
0.7%
Public
40.7%

Since Jun 2025

  • Promoters +0.29 pp
  • Public −0.29 pp
  • FIIs +0.01 pp

How it drifted, 12 quarters

Over this window the public fell from 44.6% to 40.7% — −3.9 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 54.8%, FIIs 0.2%, DIIs 0.4%, Public 44.6%.Dec '23: Promoters 54.8%, FIIs 0.2%, DIIs 0.6%, Public 44.4%.Mar '24: Promoters 54.8%, FIIs 0.2%, DIIs 0.8%, Public 44.2%.Jun '24: Promoters 58.1%, FIIs 0.1%, DIIs 0.8%, Public 41.0%.Sep '24: Promoters 58.1%, FIIs 0.1%, DIIs 0.7%, Public 41.1%.Dec '24: Promoters 58.1%, FIIs 0.1%, DIIs 0.7%, Public 41.1%.Mar '25: Promoters 58.2%, FIIs 0.2%, DIIs 0.7%, Public 40.9%.Jun '25: Promoters 58.2%, FIIs 0.2%, DIIs 0.7%, Public 41.0%.Sep '25: Promoters 58.2%, FIIs 0.2%, DIIs 0.7%, Public 41.0%.Dec '25: Promoters 58.2%, FIIs 0.2%, DIIs 0.7%, Public 41.0%.Mar '26: Promoters 58.2%, FIIs 0.3%, DIIs 0.7%, Public 40.9%.Jun '26: Promoters 58.5%, FIIs 0.2%, DIIs 0.7%, Public 40.7%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 2 holders trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Lyka Labs above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Ipca Laboratories Limited 40.45%−0.53 pp
Kunal Narendra Gandhi 10.03%+0.24 pp
Nehal Narendra Gandhi 3.60%+0.34 pp
Enai Trading And Investment Pvt. Ltd 3.04%+0.24 pp
Thermo Capital Private Limited 1.94%−0.05 pp
Dalal & Broacha Stock Broking Pvt.Ltd. 1.31%+0.12 pp
Pranay Godha 0.83%unchanged
Alisha Kunal Gandhi 0.14%unchanged
Sweta Shah 0.11%unchanged
Ushma Ronak Shah 0.09%unchanged
Lyka Generics Limited 0.06%unchanged
Neetu Godha 0.03%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Lyka Labs

Guides on how to read this kind of business and the numbers that matter.